PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders. According to GlobalData, Phase II drugs for Sleep Disorders have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PXS-4728’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PXS-4728 overview

BI-1467335 (PXS-4728) is under development for the treatment of inflammation isolated rapid eye movement sleep behavior disorder (iRBD) and Parkinson's disease. The drug candidate is administered through oral route in the form of film coated tablet and through intravenous route. It acts by targeting semicarbazide-sensitive amino-oxidase (SSAO)/vascular adhesion protein-1 and monoamine oxidase B (MAOB).

It was also under development for the treatment of chronic obstructive pulmonary disease, non-proliferative diabetic retinopathy (NPDR), non-alcoholic steatohepatitis (NASH), and cystic fibrosis.

Syntara overview

Syntara, formerly Pharmaxis, is a clinical-stage drug development company. It develops drugs for inflammatory, fibrotic and selected cancer indications diseases. The company product pipeline comprises of PXS-5505, PXS-5382, PXS-6302, PXS-4728, PXS-4699 and PXS-5370. Syntara therapeutic areas include myelofibrosis, liver and pancreatic cancer, pulmonary fibrosis, anti-fibrotic, IPF, CKD and NASH, anti-scarring, burns, established scars, isolated rapid eye movement sleep behavior disorder (IRBD), Parkinson’s disease, anti-inflammatory and multiple indications. The company provides orbital dry powder inhalers. It sells its products under the brands Bronchitol and Aridol. Syntara is headquartered in Sydney, French Forest, Australia.

For a complete picture of PXS-4728’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.